Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers
- Details
- Publication Year 2023-10-12,Volume 15,Issue #20,Page 4957
- Journal Title
- Cancers
- Abstract
- Targeting the intrinsic apoptotic pathway regulated by B-cell lymphoma-2 (BCL-2) antiapoptotic proteins can overcome the evasion of apoptosis in cancer cells. BCL-2 inhibitors have evolved into an important means of treating cancers by inducing tumor cell apoptosis. As the most extensively investigated BCL-2 inhibitor, venetoclax is highly selective for BCL-2 and can effectively inhibit tumor survival. Its emergence and development have significantly influenced the therapeutic landscape of hematological malignancies, especially in chronic lymphocytic leukemia and acute myeloid leukemia, in which it has been clearly incorporated into the recommended treatment regimens. In addition, the considerable efficacy of venetoclax in combination with other agents has been demonstrated in relapsed and refractory multiple myeloma and certain lymphomas. Although venetoclax plays a prominent antitumor role in preclinical experiments and clinical trials, large individual differences in treatment outcomes have been characterized in real-world patient populations, and reduced drug sensitivity will lead to disease recurrence or progression. The therapeutic efficacy may vary widely in patients with different molecular characteristics, and key genetic mutations potentially result in differential sensitivities to venetoclax. The identification and validation of more novel biomarkers are required to accurately predict the effectiveness of BCL-2 inhibition therapy. Furthermore, we summarize the recent research progress relating to the use of BCL-2 inhibitors in solid tumor treatment and demonstrate that a wealth of preclinical models have shown promising results through combination therapies. The applications of venetoclax in solid tumors warrant further clinical investigation to define its prospects.
- Publisher
- MDPI
- Keywords
- BCL-2 inhibitor; cancers; combination therapy; genetic mutations; venetoclax
- Research Division(s)
- Blood Cells And Blood Cancer
- PubMed ID
- 37894324
- Publisher's Version
- https://doi.org/10.3390/cancers15204957
- Open Access at Publisher's Site
https://doi.org/10.3390/cancers15204957- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-11-20 12:03:43
Last Modified: 2023-11-20 12:20:17